2024-03-29T10:38:27Zhttps://www.tdx.cat/oai/requestoai:www.tdx.cat:10803/6710992021-03-12T09:11:19Zcom_10803_183col_10803_22729
nam a 5i 4500
Hybrid diffuse optics for translational oncology and nanobiophotonics: towards a theranostic approach for emerging cancer therapies
[Barcelona] :
Universitat Politècnica de Catalunya,
2021
Accés lliure
http://hdl.handle.net/10803/671099
cr |||||||||||
AAMMDDs2021 sp ||||fsm||||0|| 0 eng|c
Mireles Núñez, Miguel Adrián,
autor
1 recurs en línia (216 pàgines)
Aplicat embargament des de la data de defensa fins el 10 d'octubre de 2020
Tesi
Doctorat
Universitat Politècnica de Catalunya. Institut de Ciències Fotòniques
2018
Universitat Politècnica de Catalunya. Institut de Ciències Fotòniques
Tesis i dissertacions electròniques
Durduran, Turgut,
supervisor acadèmic
Johansson, Johannes,
supervisor acadèmic
TDX
A pre-clinical mouse model of human clear cell renal cell carcinoma (ccRCC) was employed as a method to study the prognostic and theranostic
potential of two, non-invasive, deep tissue, diffuse optical techniques, namely broadband diffuse reflectance spectroscopy (DRS) and diffuse correlation spectroscopy (DCS). In doing so, new algorithms and methods were developed to improve the robustness and applicability
of the technology and a vision is presented for its clinical translation.
Hemodynamic biomarkers such as the total hemoglobin concentration (THC), blood oxygen saturation (SO2) and blood flow (BFI) that
were measured in a longitudinal and quantitative fashion from deep tissue layers (> 2 mm) were used to predict the outcome of an antiangiogenic
therapy, Sunitinib therapy. Hemodynamic biomarkers were shown to be useful for treatment planning prior to the onset of the therapy and, at an early stage (few days), as predictors of the therapy outcome.
The second part of this work focused on another emerging class of treatments based on the nanobiophotonics as a complementary tool
for improving other cancer therapies. The specific needs for the optimization of plasmon photo-thermal therapy based on customized
gold nanorods was studied. Based on that, it was hypothesized that the combination of DCS and DRS would enable dose planning and in vivo on-line evaluation of the treatment effects. As a means to reach this goal, this work has shown that DRS/DCS can, estimate the in vivo PEGylated gold nanorod (AuNR-PEG) concentration and detect their
accumulation and clearance from the tissues in a longitudinal manner.
Furthermore, it was shown that the injection of AuNRs-PEG do not alter the tumor hemodynamics and, that, had there been any alterations,
we could monitor its effects.
All these studies were done with a contact probe which was previously validated but was also shown to cause some systematic effects.
A proof-of-concept, scanning, non-contact system was developed and validated as a future tool to overcome these limitations.
Overall, this work contributed to bridge some of the gaps in translational oncology towards the development of personalized cancer therapies.
p
ES-BaCBU
cat
rda
ES-BaCBU
text
txt
rdacontent
informàtic
c
rdamedia
recurs en línia
cr
rdacarrier